PMID- 36559244
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221226
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 14
IP  - 12
DP  - 2022 Dec 8
TI  - Topical Sustained Delivery of Miltefosine Via Drug-Eluting Contact Lenses to 
      Treat Acanthamoeba Keratitis.
LID - 10.3390/pharmaceutics14122750 [doi]
LID - 2750
AB  - This study aimed to develop a miltefosine-eluting contact lens (MLF-CL) device 
      that would allow sustained and localized miltefosine release for the treatment of 
      Acanthamoeba keratitis. MLF-CLs were produced in three different miltefosine 
      doses by solvent-casting a thin miltefosine-polymer film around the periphery of 
      a methafilcon hydrogel, which was then lathed into a contact lens. During seven 
      days of in vitro testing, all three formulations demonstrated sustained release 
      from the lens at theoretically therapeutic levels. Based on the physicochemical 
      characterization of MLF-CLs, MLF-CL's physical properties are not significantly 
      different from commercial contact lenses in terms of light transmittance, water 
      content and wettability. MLF-CLs possessed a slight reduction in compression 
      modulus that was attributed to the inclusion of polymer-drug films but still 
      remain within the optimal range of soft contact lenses. In cytotoxicity studies, 
      MLF-CL indicated up to 91% viability, which decreased proportionally as 
      miltefosine loading increased. A three-day biocompatibility test on New Zealand 
      White rabbits revealed no impact of MLF-CLs on the corneal tissue. The MLF-CLs 
      provided sustained in vitro release of miltefosine for a week while maintaining 
      comparable physical features to a commercial contact lens. MLF-CL has a promising 
      potential to be used as a successful treatment method for Acanthamoeba keratitis.
FAU - Chen, Lin
AU  - Chen L
AUID- ORCID: 0000-0002-1187-2934
AD  - Department of Optometry and Visual Science, West China Hospital, Sichuan 
      University, Chengdu 610041, China.
AD  - Department of Ophthalmology, Affiliated Hospital of Zunyi Medical University, 
      Zunyi 563000, China.
AD  - Department of Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye 
      and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.
FAU - Kuang, Liangju
AU  - Kuang L
AUID- ORCID: 0000-0003-1799-6716
AD  - Department of Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye 
      and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.
FAU - Ross, Amy E
AU  - Ross AE
AD  - Department of Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye 
      and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.
FAU - Farhat, Wissam
AU  - Farhat W
AUID- ORCID: 0000-0002-1050-3723
AD  - Department of Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye 
      and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.
FAU - Boychev, Nikolay
AU  - Boychev N
AUID- ORCID: 0000-0003-2674-0835
AD  - Department of Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye 
      and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.
FAU - Sharfi, Sina
AU  - Sharfi S
AD  - Department of Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye 
      and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.
FAU - Kanu, Levi N
AU  - Kanu LN
AUID- ORCID: 0000-0001-6428-4696
AD  - Department of Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye 
      and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.
FAU - Liu, Longqian
AU  - Liu L
AD  - Department of Optometry and Visual Science, West China Hospital, Sichuan 
      University, Chengdu 610041, China.
FAU - Kohane, Daniel S
AU  - Kohane DS
AD  - Department of Anesthesia, Boston Children's Hospital, Harvard Medical School, 
      Boston, MA 02115, USA.
FAU - Ciolino, Joseph B
AU  - Ciolino JB
AD  - Department of Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye 
      and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.
LA  - eng
PT  - Journal Article
DEP - 20221208
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC9781349
OTO - NOTNLM
OT  - PLGA
OT  - acanthamoeba keratitis
OT  - contact lens
OT  - controlled drug delivery
OT  - miltefosine
COIS- J.B.C. and D.S.K. have a financial interest in Theroptix, a company developing a 
      contact lens drug delivery system. They are inventors of the technology, 
      co-founders, and serve as consultants. J.B.C.'s interests were reviewed and are 
      managed by Massachusetts Eye and Ear and Mass General Brigham Healthcare in 
      accordance with their conflict of interest policies. D.S.K.'s interests are 
      managed by Boston Children's Hospital in accordance with their conflict of 
      interest policies.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/24 06:01
PMCR- 2022/12/08
CRDT- 2022/12/23 01:57
PHST- 2022/10/12 00:00 [received]
PHST- 2022/11/18 00:00 [revised]
PHST- 2022/11/23 00:00 [accepted]
PHST- 2022/12/23 01:57 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/24 06:01 [medline]
PHST- 2022/12/08 00:00 [pmc-release]
AID - pharmaceutics14122750 [pii]
AID - pharmaceutics-14-02750 [pii]
AID - 10.3390/pharmaceutics14122750 [doi]
PST - epublish
SO  - Pharmaceutics. 2022 Dec 8;14(12):2750. doi: 10.3390/pharmaceutics14122750.